Third, the criminal justice approach, the other main approach to addressing violence (link to entry above), has traditionally been more geared towards violence that occurs between male youths and adults in the street and other public places—which makes up the bulk of homicides in most countries—than towards violence occurring in private settings such as child maltreatment, intimate partner violence and elder abuse—which makes up the largest share of non-fatal violence. Fourth, evidence is beginning to accumulate that a science-based public health approach is effective at preventing interpersonal violence. Human rights
The human rights approach is based on the obligations of states to respect, protect and fulfill human rights and therefore to prevent, eradicate and punish violence. It recognizes violence as a violation of many human rights: the rights to life, liberty, autonomy and security of the person; the rights to equality and non-discrimination; the rights to be free from torture and cruel, inhuman and degrading treatment or punishment; the right to privacy; and the right to the highest attainable standard of health. These human rights are enshrined in international and regional treaties and national constitutions and laws, which stipulate the obligations of states, and include mechanisms to hold states accountable. The Convention on the Elimination of All Forms of Discrimination Against Women, for example, requires that countries party to the Convention take all appropriate steps to end violence against women.
The applicant for this medicinal product is Deciphera Pharmaceuticals (Netherlands) B.V. Ripretinib was approved for medical use in the European Union in November 2021. Names
Ripretinib is the International nonproprietary name (INN) and the United States Adopted Name (USAN). References
Further reading
Schneeweiss M, Peter B, Bibi S,  et al. (May 2018). "The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis". Haematologica. 103 (5): 799–809. doi:10.3324/haematol.2017.179895. PMC 5927976. PMID 29439183. External links
"Ripretinib". Drug Information Portal. U.S. National Library of Medicine. "Ripretinib". NCI Drug Dictionary. National Cancer Institute. "Ripretinib". National Cancer Institute. 27 May 2020. Clinical trial number NCT03353753 for "Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)" at ClinicalTrials.gov